Peter Greenleaf

Peter Greenleaf

Presidente en
Maryland Venture Fund
.

Fortuna: 29 M $ al 31/05/2026

56 años
Health Technology
Finance
Commercial Services

Perfil

Peter S.
Greenleaf
is Chairman at Maryland Venture Fund, Chairman at Pelthos Therapeutics, Inc., Chairman at Revolo Biotherapeutics Ltd. since 2020, and holds an Advisory role at Petrichor Healthcare Capital Management LP.
Former roles include President, Chief Executive Officer & Director at Histogenics Corp.
(2013–2014); Chairman & Chief Executive Officer at Sucampo Pharmaceuticals LLC (2016–2018);.
President, Chief Executive Officer & Director at Aurinia Pharmaceuticals, Inc. (2019–2026); Chairman at BioDelivery Sciences International, Inc. (2018–2022); Independent Director at Antares Pharma, Inc. (2018–2022); Independent Director at Mast Therapeutics, Inc.; Director at Oldtech, Inc.; Director at Kiora Pharmaceuticals, Inc. (2018–2020); Director at Biotechnology Innovation Organization; Director at Melinta Subsidiary Corp.; Director at Tech Council of Maryland, Inc.; Director at LigoCyte Pharmaceuticals, Inc.; Independent Director at Mirna Therapeutics, Inc.; Director at Corridor Pharmaceuticals, Inc.; Director at Savara, Inc.; Director at OS Therapies, Inc.; Director at Avalo Therapeutics, Inc. (2019–2020); Director at Pharmaceutical Research & Manufacturers of America; Director at ValenzaBio, Inc.; Senior Vice President-Remicade Franchise at Centocor, Inc. (1998–2006); President at MedImmune LLC (2006–2013); Principal at US Healthcare, Inc.; Principal at Hallmark Cards, Inc.; President at MedImmune Ventures, Inc. (2010–2013); Principal at Roche Diagnostics Corp.
(1996–1998); Trustee at The University of Maryland Baltimore Foundation, Inc.; District Manager at Boehringer Mannheim GmbH (1996–1998); President at AstraZeneca PLC (2006–2013).
Education includes an MBA from St. Joseph's University and undergraduate studies at Western Connecticut State University.

Participaciones conocidas en empresas públicas

EmpresaFechaNúmero de accionesValoraciónFecha de valoración
02/03/2026 1.840.379 ( 1,43 % ) 28 M $ 31/05/2026
0,71 %
02/04/2026 24.681 ( 0,71 % ) 653 306 $ 31/05/2026

Últimas noticias acerca de Peter Greenleaf

Cargos activos de Peter Greenleaf

EmpresasCargoInicio
Presidente -
Presidente 17/12/2020
Consultor / Asesor -

Antiguos cargos conocidos de Peter Greenleaf.

EmpresasCargoFin
AURINIA PHARMACEUTICALS INC. Director Ejecutivo 23/03/2026
ANTARES PHARMA, INC. Director/Miembro de la Junta 24/05/2022
BIODELIVERY SCIENCES INTERNATIONAL, INC. Presidente 22/03/2022
AVALO THERAPEUTICS, INC. Director Ejecutivo 15/04/2019
KIORA PHARMACEUTICALS, INC. Director/Miembro de la Junta 03/01/2020
Ver el detalle de la experiencia de Peter Greenleaf.

Formación de Peter Greenleaf.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

69

Relaciones de 1er grado

33

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas33

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Consumer Non-Durables

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Miscellaneous

Finance

Commercial Services

Health Technology

Health Technology

Health Technology

Boehringer Mannheim GmbH

Health Technology

Health Technology

Finance

Health Technology

Health Technology

-40%: Ampliación de plazo extraordinaria
d
:
:
APROVECHAR LA PROMOCIÓN